Investigation of the Immune Response to Malaria Vaccines

Objective: This review article synthesizes the molecular, cellular, and structural mechanisms governing host immune responses to modern malaria vaccines. It critically evaluates current correlates of protection, adjuvant modulation pathways, and the biological bottlenecks driving individual variations in vaccine immunogenicity.
Methodology: Following a structured scoping methodology adapted from the PRISMA guidelines, a systematic evaluation of literature published between January 2015 and April 2026 was conducted across PubMed, Scopus, and Cochrane databases. Analysis was restricted to human clinical trial datasets (Phases I–III) and cohort studies examining licensed VLP platforms and advanced whole-sporozoite candidates.
Results: Humoral protection hinges on inducing high-avidity IgG antibodies against the central circumsporozoite protein (CSP) NANP repeat region. Next-generation high-density VLPs (R21) maximize B-cell receptor cross-linking compared to carrier-diluted arrays (RTS, S), yielding enhanced antibody avidity. Sustaining these protective thresholds requires helper responses driven by circulating T follicular helper (cTfh) cells and polyfunctional CD4+ T-cells, which are selectively expanded by advanced liposome-based (AS01) and saponin-nanoparticle (Matrix-M) adjuvants. Current platforms fail to trigger intrahepatic cytotoxic CD8+ T-cell responses to clear escaped parasites. Host-specific factors induces T-cell exhaustion, maternal antibody masking in young infants, and nutritional status to introduce substantial immunogenic variability across endemic populations.
Conclusion: Resolving rapid decay of vaccine-induced immunity is critical for absolute malaria eradication. Future strategies must optimize alternative delivery mechanisms, such as fractional dosing schedules, to enhance antibody durability. Concurrently, transitioning toward multi-stage polyvalent vaccine formulations and lipid-nanoparticle (LNP)-formulated mRNA platforms will be vital to trigger necessary cytotoxic CD8+ responses and overcome regional parasite polymorphisms.